Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors

Abstract

Concurrent presence of EGFR and KRAS mutations in non-small-cell lung cancer (NSCLC) is relatively rare. Five case reports of multiple mutations of those genes are presented.

Activation of both mutations does not necessarily pose a negative prediction.

Keywords

• NSCLC
• EGFR
• KRAS
• mutation
• multiplicity
• clonality